Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer
Therapeutic Advances in Medical Oncology
Published online on August 04, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Tepotinib received Food and Drug Administration approval for advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation (METex14m) based on a single-arm trial. However, the comparative effectiveness between tepotinib and ...
Background:Tepotinib received Food and Drug Administration approval for advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation (METex14m) based on a single-arm trial. However, the comparative effectiveness between tepotinib and ...